Wiviann Ottosson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wiviann Ottosson has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Laura Ann Rechner
Department of Oncology, Radiotherapy Research Unit, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark
4 shared publications - Ane Lindegaard Appelt
Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Health Technology, Technical University of Denmark, Copenhagen, Denmark
3 shared publications - Laura Patricia Kaplan
Department of Oncology and Palliative Units, Zealand University Hospital, Næstved, Denmark
3 shared publications - Lone Hoffmann
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
3 shared publications - Mikkel Drøgemüller Lund
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark
3 shared publications - Patrik Sibolt
Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark
3 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Elsevier in Radiotherapy and Oncology
Is it tumor burden? A critical analysis of postirradiation lymphopenia in lung cancer patients
- 18 November 2026
- Published by Elsevier in Radiotherapy and Oncology
Open AccessIs it tumor burden? A critical analysis of postirradiation lymphopenia in lung cancer patients
- Open Access
- 19 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 55, 104190
Multicenter Study of Dose Accumulation for Reirradiation: Intercenter Variation in Radiobiological Dose Scaling Introduces Clinically Relevant Differences
- 19 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 55, 104190
Open AccessMulticenter Study of Dose Accumulation for Reirradiation: Intercenter Variation in Radiobiological Dose Scaling Introduces Clinically Relevant Differences
- Open Access
- 20 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111293
Development of a treatment planning protocol for the multi-centre reirradiation CURE Lung trial
- 20 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111293
Open AccessDevelopment of a treatment planning protocol for the multi-centre reirradiation CURE Lung trial
- Open Access
- 9 July 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 872-878
A comprehensive national audit of radiotherapy retreatment numbers, sites and indications
Background and purpose: Reirradiation has seen increased interest and clinical use; however, robust data on patient numbers and treatment indications are missing. As a precursor to a prospective national reirradiation registry, a comprehensive national audit of reirradiation was performed. Patients/materials and methods: Radiotherapy retreatment courses in 2023 were audited by all (eight) radiotherapy centres in Denmark. Six centres extended the evaluation to include 2021–22, and three of these also evaluated preceding years. Reirradiation was defined according to the ESTRO/EORTC consensus (i.e. treatment volume overlap or cumulative dose toxicity risk) using 3 months threshold between the primary and reirradiation courses. Reirradiation courses were further stratified into curative/ablative and palliative treatments by prescription dose. Results: The total number of radiotherapy patients at Danish centres in 2023 was 17,424. Of these, 3,163 received retreatment, including 1,471 reirradiation courses (1,035 palliative; 436 curative/ablative). From 2014 to 2023, absolute numbers for both retreatment and reirradiation increased. We found large variation in prescription doses and fractionation schedules used for reirradiation. Widely used palliative prescriptions were 8Gy/1 fraction (F), 20Gy/4F and 30Gy/10F; stereotactic prescriptions of 20Gy/1F or 27Gy/3F in brain and 45Gy/3F in lung; and a variety of curative treatments schedules. Palliative reirradiations were primarily thoracic (29%), spine (25%), and abdominal/pelvic (22%) and curative/ablative reirradiations were primarily breast (29%) and lung stereotactic (23%). Interpretation: This is the first comprehensive national audit of reirradiation, demonstrating an increasing number of patients being treated, using a wide variety of dose prescriptions and fractionation schedules.
- 9 July 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 872-878
Open AccessA comprehensive national audit of radiotherapy retreatment numbers, sites and indications
Background and purpose: Reirradiation has seen increased interest and clinical use; however, robust data on patient numbers and treatment indications are missing. As a precursor to a prospective national reirradiation registry, a comprehensive national audit of reirradiation was performed. Patients/materials and methods: Radiotherapy retreatment courses in 2023 were audited by all (eight) radiotherapy centres in Denmark. Six centres extended the evaluation to include 2021–22, and three of these also evaluated preceding years. Reirradiation was defined according to the ESTRO/EORTC consensus (i.e. treatment volume overlap or cumulative dose toxicity risk) using 3 months threshold between the primary and reirradiation courses. Reirradiation courses were further stratified into curative/ablative and palliative treatments by prescription dose. Results: The total number of radiotherapy patients at Danish centres in 2023 was 17,424. Of these, 3,163 received retreatment, including 1,471 reirradiation courses (1,035 palliative; 436 curative/ablative). From 2014 to 2023, absolute numbers for both retreatment and reirradiation increased. We found large variation in prescription doses and fractionation schedules used for reirradiation. Widely used palliative prescriptions were 8Gy/1 fraction (F), 20Gy/4F and 30Gy/10F; stereotactic prescriptions of 20Gy/1F or 27Gy/3F in brain and 45Gy/3F in lung; and a variety of curative treatments schedules. Palliative reirradiations were primarily thoracic (29%), spine (25%), and abdominal/pelvic (22%) and curative/ablative reirradiations were primarily breast (29%) and lung stereotactic (23%). Interpretation: This is the first comprehensive national audit of reirradiation, demonstrating an increasing number of patients being treated, using a wide variety of dose prescriptions and fractionation schedules.
- Open Access
- 4 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 207, 110906
Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial
- 4 May 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 207, 110906
Open AccessEsophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial
- 30 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (11) , 1496-1501
Interim analysis of patient-reported outcome compliance and dosimetry in a phase 3 randomized clinical trial of oesophagus-sparing spinal radiotherapy
The randomized clinical trial ESO-SPARE investigates if oesophagus-sparing radiotherapy (RT) can reduce dysphagia in patients with metastatic spinal cord compression (MSCC). Patient-reported outcome (PRO) is the only follow-up measure. Due to the fragile patient population, low respondent compliance was anticipated. We performed a planned interim analysis of dosimetry and respondent compliance, to ensure that the protocol requirements were met. Patients >18 years referred for cervical/thoracic MSCC radiotherapy in 1-10 fractions were included from two centres. Patients were randomized (1:1) to standard RT or oesophagus-sparing RT, where predefined oesophageal dose constraints were prioritized over target coverage. Patients completed a trial diary with daily reports of dysphagia for 5 weeks (PRO-CTC-AE) and weekly quality of life reports for 9 weeks (QLQ-C30, EQ-5D-5L). According to power calculation, 124 patients are needed for primary endpoint analysis. The sample size was inflated to 200 patients to account for the fragile patient population. The co-primary endpoints, peak patient-reported dysphagia, and preserved ability to walk (EQ-5D-5L), are analysed at 5 and 9 weeks, respectively. The interim analysis was conducted 90 days after the inclusion of patient no 100. Respondent compliance was assessed at 5 and 9 weeks. In all RT plans, oesophagus and target doses were evaluated regarding adherence to protocol constraints. From May 2021 to November 2022, 100 patients were included. Fifty-two were randomized to oesophagus-sparing RT. In 23% of these plans, oesophagus constraints were violated. Overall, the dose to both target and oesophagus was significantly lower in the oesophagus-sparing plans. Only 51% and 41% of the patients were evaluable for co-primary endpoint analysis at five and nine weeks, respectively. Mortality and hospitalization rates were significantly larger in patients who completed <4 days PRO questionnaires. Compliance was lower than anticipated and interventions to maintain study power are needed.
- 30 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (11) , 1496-1501
Interim analysis of patient-reported outcome compliance and dosimetry in a phase 3 randomized clinical trial of oesophagus-sparing spinal radiotherapy
The randomized clinical trial ESO-SPARE investigates if oesophagus-sparing radiotherapy (RT) can reduce dysphagia in patients with metastatic spinal cord compression (MSCC). Patient-reported outcome (PRO) is the only follow-up measure. Due to the fragile patient population, low respondent compliance was anticipated. We performed a planned interim analysis of dosimetry and respondent compliance, to ensure that the protocol requirements were met. Patients >18 years referred for cervical/thoracic MSCC radiotherapy in 1-10 fractions were included from two centres. Patients were randomized (1:1) to standard RT or oesophagus-sparing RT, where predefined oesophageal dose constraints were prioritized over target coverage. Patients completed a trial diary with daily reports of dysphagia for 5 weeks (PRO-CTC-AE) and weekly quality of life reports for 9 weeks (QLQ-C30, EQ-5D-5L). According to power calculation, 124 patients are needed for primary endpoint analysis. The sample size was inflated to 200 patients to account for the fragile patient population. The co-primary endpoints, peak patient-reported dysphagia, and preserved ability to walk (EQ-5D-5L), are analysed at 5 and 9 weeks, respectively. The interim analysis was conducted 90 days after the inclusion of patient no 100. Respondent compliance was assessed at 5 and 9 weeks. In all RT plans, oesophagus and target doses were evaluated regarding adherence to protocol constraints. From May 2021 to November 2022, 100 patients were included. Fifty-two were randomized to oesophagus-sparing RT. In 23% of these plans, oesophagus constraints were violated. Overall, the dose to both target and oesophagus was significantly lower in the oesophagus-sparing plans. Only 51% and 41% of the patients were evaluable for co-primary endpoint analysis at five and nine weeks, respectively. Mortality and hospitalization rates were significantly larger in patients who completed <4 days PRO questionnaires. Compliance was lower than anticipated and interventions to maintain study power are needed.
- 1 June 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (3) , 432-437
The advantage of deep-inspiration breath-hold and cone-beam CT based soft-tissue registration for locally advanced lung cancer radiotherapy
- 1 June 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (3) , 432-437
The advantage of deep-inspiration breath-hold and cone-beam CT based soft-tissue registration for locally advanced lung cancer radiotherapy